Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: A meta-analysis

Journal of Interventional Cardiology

Volumn 27, Issue 4, 2014, Pages 356-364

  Zhao, Shijie ^a   Qi, Guoxian ^a   Tian, Wen ^a   Chen, Ling ^a   Sun, Yujiao ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NITROPRUSSIDE SODIUM; PLACEBO; VASODILATOR AGENT;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR PARAMETERS; CORRECTED TIMI FRAME COUNT; DATA BASE; DRUG EFFECT; HEART DISEASE; HUMAN; META ANALYSIS; MYOCARDIAL BLUSH GRADE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ST SEGMENT RESOLUTION; THROMBOLYSIS FLOW GRADE; THROMBOLYSIS IN MYOCARDIAL INFARCTION; TREATMENT OUTCOME; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON;

HUMANS; MYOCARDIAL INFARCTION; NITROPRUSSIDE; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; VASODILATOR AGENTS;

EID: 84905035643     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12133     Document Type: Article

References (42)

1. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-292.
2. Rezkalla SH, Kloner RA., Coronary no-reflow phenomenon: From the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008; 72: 950-957.
3. Bates JN, Baker MT, Guerra RJ, et al. Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol 1991; 42 Suppl: S157-S165.
4. Kuo L, Chilian WM, Davis MJ., Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. Am J Physiol 1991; 261: H1706-H1715.
5. Myers PR, Banitt PF, Guerra RJ, et al. Role of the endothelium in modulation of the acetylcholine vasoconstrictor response in porcine coronary microvessels. Cardiovasc Res 1991; 25: 129-137.
6. Higgins J, Green S,. Cochrane handbook for systematic reviews of interventions version 5.0. 2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org., 2010.
7. Begg CB, Mazumdar M., Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
8. Zhao YJ, Fu XH, Ma XX, et al. Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction. Exp Ther Med 2013; 6: 479-484.
9. Niccoli G, Rigattieri S, De Vita MR, et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: The REOPEN-AMI study (intracoronary nitroprusside versus adenosine in acute myocardial infarction). JACC Cardiovasc Interv 2013; 6: 580-589.
10. Nayel AE, Elabd AA, Fathalla H., Role of intracoronary injection of Na-nitroprusside in preventing no-reflow phenomenon in patients with STEMI during primary percutaneous coronary intervention. JACC Cardiovasc Interv 2013; 6: S7-S8.
11. Sakamoto H, Shimamoto S, Kawase Y, et al. Effect of nitroprusside on reducing infarct size after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2010; 55: A104-A968.
12. Pan W, Wang LF, Yu JH, et al. Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction. Chinese Med J (Engl) 2009; 122: 2718-2723.
13. Shinozaki N, Ichinose H, Yahikozawa K, et al. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int Heart J 2007; 48: 423-433.
14. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 2006; 152: 887-889.
15. Oremus M, Wolfson C, Perrault A, et al. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord 2001; 12: 232-236.
16. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-2518.
17. Yun KH, Jeong MH, Oh SK, et al. Response of high-sensitivity C-reactive protein to percutaneous coronary intervention in patients with acute coronary syndrome. Heart Vessels 2009; 24: 175-180.
18. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193-1199.
19. Rezkalla SH, Kloner RA., No-reflow phenomenon. Circulation 2002; 105: 656-662.
20. Rittersma SZ, van der Wal AC, Koch KT, et al. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: A pathological thrombectomy study in primary percutaneous coronary intervention. Circulation 2005; 111: 1160-1165.
21. Myers PR, Banitt PF, Guerra RJ, et al. Characteristics of canine coronary resistance arteries: Importance of endothelium. Am J Physiol 1989; 257: H603-H610.
22. Hamada S, Nishiue T, Nakamura S, et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. J Am Coll Cardiol 2001; 38: 666-671.
23. Ndrepepa G, Tiroch K, Keta D, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 2010; 3: 27-33.
24. Araszkiewicz A, Lesiak M, Grajek S, et al. Effect of microvascular reperfusion on prognosis and left ventricular function in anterior wall myocardial infarction treated with primary angioplasty. Int J Cardiol 2007; 114: 183-187.
25. Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation 1999; 99: 1945-1950.
26. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-888.
27. Niccoli G, Cosentino N, Spaziani C, et al. No-reflow: Incidence and detection in the cath-lab. Curr Pharm Des 2013; 19: 4564-4575.
28. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125-130.
29. van T HA, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302-2306.
30. Porto I, Burzotta F, Brancati M, et al. Relation of myocardial blush grade to microvascular perfusion and myocardial infarct size after primary or rescue percutaneous coronary intervention. Am J Cardiol 2007; 99: 1671-1673.
31. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105: 1909-1913.
32. Stone GW, Peterson MA, Lansky AJ, et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 2002; 39: 591-597.
33. Su Q, Li L, Naing KA, et al. Safety and effectiveness of nitroprusside in preventing no-reflow during percutaneous coronary intervention: A systematic review. Cell Biochem Biophys 2014; 68: 201-206.
34. Sorajja P, Gersh BJ, Costantini C, et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005; 26: 667-674.
35. Angeja BG, Gunda M, Murphy SA, et al. TIMI myocardial perfusion grade and ST segment resolution: Association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 2002; 105: 282-285.
36. Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-1780.
37. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: The AMISTAD-2 trial. Eur Heart J 2006; 27: 2400-2405.
38. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet 2007; 370: 1483-1493.
39. Wu M, Huang Z, Xie H, et al. Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: A systematic review and meta-analysis. PLoS ONE 2013; 8: e78231.
40. Aung NK, Li L, Su Q, et al. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev 2013; 6: CD009503.
41. Parham WA, Bouhasin A, Ciaramita JP, et al. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation 2004; 109: 1236-1243.
42. Fugit MD, Rubal BJ, Donovan DJ., Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 2000; 12: 80-85.